Phase II study of ionidamine in patients with metastatic breast cancer - An Eastern Cooperative Oncology Group study

H. Ian Robins*, Donna S. Neuberg, Al B. Benson, Kishan J. Pandya, Douglass C. Tormey

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations


The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.

Original languageEnglish (US)
Pages (from-to)397-399
Number of pages3
JournalInvestigational New Drugs
Issue number4
StatePublished - Nov 1 1990



  • breast cancer
  • lonidamine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this